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Abstract
Acute lung injury (ALI) and acute respiratory distress syndrome
(ARDS) are life-threatening disorders that have substantial adverse
effects on outcomes in critically ill patients. ALI/ARDS develops in
response to pulmonary or extrapulmonary injury and is charac-
terized by increased leakage from the pulmonary microvasculature
and excessive infiltration of polymorphonuclear cells into the lung.
Currently, no therapeutic strategies are available to control these
fundamental pathophysiological processes in human ALI/ARDS. In
a variety of animal models and experimental settings, the purine
nucleoside adenosine has been demonstrated to regulate both
endothelial barrier integrity and polymorphonuclear cell trafficking
in the lung. Adenosine exerts its effects through four G-protein-
coupled receptors (A1, A2A, A2B, and A3) that are expressed on
leukocytes and nonhematopoietic cells, including endothelial and
epithelial cells. Each type of adenosine receptor (AR) is charac-
terized by a unique pharmacological and physiological profile. The
development of selective AR agonists and antagonists, as well as
the generation of gene-deficient mice, has contributed to a
growing understanding of the cellular and molecular processes
that are critically involved in the development of ALI/ARDS.
Adenosine-dependent pathways are involved in both protective
and proinflammatory effects, highlighting the need for a detailed
characterization of the distinct pathways. This review summarizes
current experimental observations on the role of adenosine
signaling in the development of acute lung injury and illustrates that
adenosine and ARs are promising targets that may be exploited in
the development of innovative therapeutic strategies.
Introduction
Acute lung injury (ALI) and acute respiratory distress syn-
drome (ARDS) are life-threatening syndromes that are
characterized by severe hypoxemia, decreased lung com-
pliance, and diffuse bilateral infiltrates without evidence of left
atrial hypertension. ALI and ARDS develop during the course
of direct lung injury such as pneumonia, acid aspiration,
ischemia/reperfusion after lung transplantation, or direct
traumatic damage. Alternatively, they may develop secondary
to systemic inflammatory diseases such as sepsis, extra-
pulmonary trauma, transfusion, or cardiopulmonary resus-
citation [1]. Despite recent advances in our understanding of
the pathophysiology, therapeutic options are limited and
focus on treating the underlying disease and preventing
secondary lung damage by mechanical ventilation with low
tidal volumes [2]. Nevertheless, mortality remains high at
40%, and the incidence of ALI/ARDS of approximately 80/
100,000 person-years in the USA [3] underlines the impor-
tance of these entities to critical care medicine and public
health in general.
The early phase of ALI/ARDS is characterized by an exces-
sive inflammatory response that results in disruption of the
endothelial barrier. As a consequence, a protein-rich lung
edema develops and impairs pulmonary function [1]. The
pulmonary endothelium is also critically involved in the
recruitment and transmigration of polymorphonuclear cells
(PMNs) into the lung [4]. PMNs are the leukocytes that
predominantly mediate the initial phase of ALI. Numerous
experimental and clinical observations have established a key
role for PMNs in the pathogenesis of ALI in animals and
patients. For instance, PMN depletion attenuates experimental
lung damage, pulmonary function in neutropenic patients with
lung injury can deteriorate as neutropenia resolves [5], and
persistent pulmonary neutrophilia in ARDS is associated with
poor outcomes [6].
Adenosine, an ancient endogenous molecule, has been
shown to be a potent modulator of endothelial permeability
[7], PMN migration, and PMN activation [8]. Adenosine
Review
Bench-to-bedside review: Adenosine receptors – promising
targets in acute lung injury?
Carsten P Schepp1,2 and Jörg Reutershan1
1Department of Anesthesiology and Intensive Care Medicine, University Hospital Tübingen, Hoppe-Seyler-Strasse, D-72076 Tübingen, Germany
2Current address: Department of Anesthesiology and Intensive Care Medicine, University Hospital Regensburg, Franz-Josef-Strauß-Allee, 92042
Regensburg, Germany
Corresponding author: Jörg Reutershan, joerg.reutershan@uni-tuebingen.de
Published: 11 September 2008 Critical Care 2008, 12:226 (doi:10.1186/cc6990)
This article is online at http://ccforum.com/content/12/5/226
© 2008 BioMed Central Ltd
ADA = adenosine deaminase; ALI = acute lung injury; AR = adenosine receptor; ARDS = acute respiratory distress syndrome; BAL = broncho-
alveolar lavage; CXCL = C-X-C chemokine ligand; I/R = ischemia/reperfusion; LPS = lipopolysaccharide; PMN = polymorphonuclear cell; VILI =
ventilator-induced lung injury.Page 2 of 8
(page number not for citation purposes)
Critical Care    Vol 12 No 5 Schepp and Reutershan
signals through specific adenosine receptors (ARs) that are
expressed on a variety of cells, including leukocytes and
nonhematopoietic cells. Each of the four known ARs exhibits
a distinct pharmacological and physiological profile [9]. A
growing understanding of this multifaceted adenosine signal-
ing complex has paved the way for new approaches to
interfere with the inflammatory cascade during ALI. This
review summarizes current experimental findings regarding
the roles played by adenosine and ARs in pulmonary inflam-
mation. Adenosine-dependent pathways in ALI are high-
lighted and the potential of ARs as therapeutic targets is
critically discussed.
The physiological role of adenosine and
adenosine receptors
Adenosine is a purine nucleoside with a short in vivo half-life
of 1.5 seconds [10]. It is generated by intracellular hydrolysis
from adenine nucleotides or S-adenosyl homocysteine. To
exert its messenger function, adenosine is subsequently
released into the extracellular space either by specific
nucleoside transporters [11] or nonspecifically, upon damage
to the cell membrane. In addition, adenine nucleotides can be
extracellularly hydrolyzed to adenosine. Hydrolysis is media-
ted by the two enzymes ectoapyrase (CD39) and ecto-5’-
nucleotidase (CD73; Figure 1) [12]. Adenosine is constitu-
tively present in the extracellular space at a concentration of
1 μmol/l in resting tissues [13] and can increase up to 100-
fold in response to oxidative stress or ischemia [14]. Its
systemic bioavailabilty is limited because of its rapid
reuptake, degradation by adenosine deaminase to inosine, or
rephosphorylation by adenosine kinase.
Apart from its central role in energy metabolism, adenosine-
dependent pathways are also involved in a variety of other
physiological and pathophysiological events. Acknowledge-
ment of the potent negative dromotropic and coronary
vasodilatory capacity has led to the use of adenosine to treat
supraventricular tachycardias. In the peripheral and central
nervous systems, adenosine is involved in a variety of
processes, including cerebral blood flow, pain transmission,
basal ganglia function, and seizure activity [15].
Adenosine exerts its effects through specific cell-surface
receptors that are present on a wide variety of cells, including
leukocytes and endothelial cells. Specific antagonism of
adenosine-dependent effects by methylxanthines, caffeine,
and theophylline originally led to the discovery of these
receptors. Four subtypes of ARs have been described: A1,
A2A, A2B, and A3. All ARs are members of the superfamily of
G-protein-coupled receptors [9]. Each AR exhibits a distinct
pattern of tissue distribution, intracellular signaling, and
pharmacokinetic characteristics (Table 1). Each receptor
subtype shows high interspecies homology among mammals
[9]. The availability of selective agonists and antagonists
[16,17] and gene-deficient mice for each receptor has led to a
growing understanding of the biologic functions of ARs [18].
Role of adenosine in inflammation
Acknowledgment of adenosine as a potential mediator of
inflammatory responses has emerged from experimental
studies that showed that adenosine exhibited protective
effects in various models of ischemia/reperfusion (I/R) injury
[17]. I/R injury is characterized by excessive invasion of
activated PMNs into tissues in which blood flow has been
restored after a period of ischemia. Clinical homologs of I/R
include reperfusion after organ transplantation or myocardial
infarction. Presence and extent of I/R injury substantially
affect the outcome and the success of therapeutic strategies
that aim to re-establish blood flow in ischemic organs.
Pharmacological blockade of PMN infiltration into reperfused
tissues mitigates the extent of I/R injury [19]. Both PMN
activation and trafficking are critically regulated by adenosine.
This includes the generation of superoxide, adhesion and
migration, as well as secretion of cytokines and growth
factors [20]. PMNs express all four ARs [8], enabling these
central cells of the innate immune system to integrate various
adenosine-dependent signaling pathways.
A canine model of myocardial I/R injury exemplifies the broad
immunoregulatory capacity of the adenosine-dependent signal-
ing complex [21]. Treatment with an A2A agonist reduced PMN
accumulation in the postischemic tissue and reduced infarct
size. The same agonist attenuated superoxide generation and
adherence to endothelial cells. In addition to PMNs, platelets,
macrophages, mast cells, and T cells contribute to adenosine-
dependent effects, although their impact on pulmonary
inflammatory responses is less obvious [17].
Adenosine in pulmonary inflammation
Involvement of adenosine in PMN-dependent inflammatory
responses has evoked growing interest in studying the role
played by adenosine and AR in ALI. Adenosine is
constitutively released into the distal airways of C57Bl6 mice
[22]. In addition, pulmonary expression of all four ARs has
been demonstrated in the lungs of mice [23] and humans [24].
Chronically elevated levels of adenosine may occur as a
result of defective metabolism. Gene-deficient mice that fail
to express adenosine deaminase (ADA-/- mice) succumb to
severe pulmonary inflammation at the age of 3 weeks. This
inflammation is characterized by an infiltration with eosino-
phils [25]. In addition, elevated adenosine levels induce
pulmonary fibrosis in these mice [26], which is a typical
complication in the delayed phase of ARDS. The phenotype
observed with ADA-/- mice provides compelling evidence that
activation of the adenosine signaling complex aggravates
chronic airway inflammatory diseases such as asthma and
chronic obstructive pulmonary disease [27,28]. In contrast,
protective effects of adenosine have been demonstrated by
others [29], emphasizing the complexity of adenosine
signaling. Although adenosine has been identified as a pivotal
mediator in chronic pulmonary inflammation, its effects in ALI
have only recently become the focus of experimental research.Page 3 of 8
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Numerous studies have established a critical role for adeno-
sine in the regulation of pulmonary microvascular permea-
bility, a process that is profoundly disturbed in ALI. The
majority of ALI patients show impaired alveolar fluid
clearance, with a low maximal clearance being a predictor for
decreased mortality [30]. Alveolar fluid clearance is reduced
by activation of murine A1, but it is increased by A2A and A3
activation [22]. In a model of lipopolysaccharide (LPS)-
induced pulmonary inflammation, administration of 2-chloro-
adenosine, an unselective AR agonist, leads to markedly
decreased fluid accumulation in the lung of guinea pigs [31].
In pigs, administration of adenosine partly prevented the LPS-
induced increase in microvascular permeability, as assessed
by extravascular lung water [32]. Protective effects on
pulmonary microvascular leakage have also been demon-
strated in the model of fat emulsion induced ALI [33],
implicating adenosine as a key molecule in the regulation of
endothelial integrity and pulmonary fluid balance.
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Figure 1
Sources of extracellular adenosine. Intracellular hydrolysis of adenine nucleotides or S-adenosylhomocysteine (SAHC) yields adenosine that is
released via specific nucleoside transporters (NT) or nonspecifically upon cell membrane damage. In the extracellular space, adenine nucleotides
are hydrolyzed by ectoapyrase (CD39) and ecto-5’-nucleotidase (CD73). Adenosine binds to specific G-protein-coupled receptors, namely the
adenosine receptors (AR), which initiate various cellular responses.
Table 1
Relevant functional parameters of adenosine receptors
A1 A2A A2B A3
Coupled G proteins Gi, Go Gs, Golf, G15/16 Gs, Gq Gi, Gq
Intracellular messengers ↓ cAMP ↑ cAMP ↑ cAMP ↓ cAMP
↑ IP3/DAG ↑ IP3 ↑ IP3/DAG ↑ IP3/DAG
↑ Arachidonate
↑ PEtOH
Selected biologic functions Bradycardia ↓ Platelet aggregation Relaxation of vascular  ↑ Mediator release from 
Antinociception Vasodilation smooth muscle cells mast cells (mice)
Ischemic preconditioning Protection against  Stimulation of mast cell  Preconditioning
↓ Lipolysis, ischemic damage mediator release
↓ Glomerular filtration
Potencya (EC50 [μmol/l]) 0.31 0.73 23.5 0.29
aPotency as reflected by intracellular cAMP levels. Adapted from [8,9,18,55]. DAG, diacylglycerol; ED50, 50% effective dose; IP3,
inositoltriphosphate; PetOH, phosphatidylethanol.Mechanical ventilation, which is required to achieve adequate
gas exchange in ARDS patients, can promote lung inflamma-
tion, especially when high tidal volumes are applied (venti-
lator-induced lung injury [VILI]) [2]. However, the underlying
mechanisms are unclear. Mechanical ventilation of rats leads
to increased levels of AMP and adenosine in bronchoalveolar
lavage (BAL) fluid. This increase can be attenuated by lung-
protective ventilation with low tidal volumes and application of
positive end-expiratory pressure [34]. A similar increase in
adenosine levels in BAL fluid has been demonstrated in
mechanically ventilated mice. This increase is paralleled by
induction of the rate-limiting enzymes for extracellular adeno-
sine generation CD39 and CD73 on pulmonary endothelium
and epithelium. Treatment of these mice with an A2B
antagonist increased albumin leakage into the BAL fluid and
decreased survival. ALI was enhanced in CD39-/- and CD73-/-
mice, as indicated by impaired oxygenation and increased
protein content of the BAL fluid, increased PMN infiltration,
and increased lung water content [35]. These findings
suggest that upregulation of adenosine production in
response to mechanical ventilation mediates protection from
ALI. Interestingly, pulmonary PMN infiltration after hypoxia, a
potent inflammatory stimulus in the lung, was also increased
in CD39-/- and CD73-/- mice [36].
In humans, the role played by adenosine in acute pulmonary
inflammation has not been studied systematically. Cultured
human bronchial epithelial cells secrete adenosine when they
are subjected to repeated mechanical stretching - a model
that mimics cyclic opening and closing of distal airway
structures during mechanical ventilation [35]. Shear stress on
endothelial cells is also accompanied by a rise in extracellular
ATP, soluble ATPase, and 5’-nucleotidase activity [37]. In
addition, secreted adenosine reduces paracellular endothelial
permeability in vitro [35], suggesting that adenosine serves
as a physiological feedback mediator to protect the lung
against mechanical stress. Whether insufficient production of
adenosine promotes VILI in some patients has not been
studied, but this might be one pathway that underlies the
protective effects of ventilation with low tidal volumes.
One ligand - four receptors
A1 - bad cop?
The AR subtype A1 is expressed at low levels in the lung,
whereas higher levels are found in the central nervous system
and various other peripheral tissues [24]. In ADA-/- mice A1
expression was identified on endothelial cells, airway epi-
thelial cells and alveolar epithelial cells, and it was most
pronounced on alveolar macrophages [29]. Activation of A1
results in decreased adenylate cyclase activity via pertussis-
toxin sensitive Gi and Go proteins. A1 also signals through
phospholipase C via Gβγ subunits, pertussis-toxin sensitive
K+ channels, and KATP channels [9,18,38]. Aside from its
numerous effects on the central nervous system, A1 signaling
plays a pivotal role in manifesting I/R injury in various tissues
[38,39].
Functional blocking of A1 with a selective antagonist reduced
I/R injury in the feline lung [40]. The same antagonist was
examined in endotoxin-induced lung injury in cats. In that
study, intralobar arterial infusion of endotoxin caused dose-
dependent pulmonary infiltration with PMNs and alveolar
edema. Application of the A1 antagonist before and after the
maximum dose of endotoxin abolished alveolar injury almost
completely [41]. The significance of A1 signaling in pulmonary
fluid homeostasis has been demonstrated in a variety of other
experimental settings. In mice, activation of A1 but not of A2A
and A3 reduced alveolar fluid clearance [22] and may have
led to alveolar fluid accumulation. Consistent with these data,
pretreatment with an A1 antagonist blocked the increase in
pulmonary capillary filtration in a canine model of ALI [42].
However, others have found contrary results. In rabbits, A1
activation reduced LPS-induced pulmonary edema formation.
A2 activation had a similar effect but it also reduced
pulmonary vasoconstriction [43].
The predominant proinflammatory role of A1, as shown in
different models of ALI, is counter to its protective function in
chronically inflamed airways. Deletion of A1 in ADA-/- mice
resulted in markedly enhanced pulmonary inflammation,
suggesting an anti-inflammatory role of A1 in chronically
inflamed airways [29].
In humans, the impact of A1 signaling in ALI is not known.
Interestingly, LPS has been shown to be a ligand for A1 on
human pulmonary endothelial cells. LPS displaces a selective
A1 antagonist from the receptor in a dose-dependent and
competitive manner. Binding of LPS to A1 leads to increased
secretion of interleukin-6 and thromboxane A2, which can be
significantly reduced by administration of a selective A1
antagonist [44]. The influence of A1 signaling on pulmonary
fluid homeostasis that has been observed in a variety of
animal models remains to be elucidated in humans.
A2A - good cop?
A2A consists of 410 amino acids with an extended carboxyl-
terminus, making A2A the largest of all ARs. The highest expres-
sion of A2A is found in the central nervous system, spleen,
thymus, leukocytes, and platelets, whereas intermediate levels
are found in the lung [9,18,38]. In macrophages, A2A
expression is increased more than 100-fold upon LPS exposure
[45]. Activation of A2A results in an increased adenylate cyclase
activity by signaling via cholera-toxin sensitive Gs proteins. A2A
coupling to Golf and G15/16 has also been demonstrated,
leading to increased adenylate cyclase activity and inositol
triphosphate increase, respectively. Main cellular responses
include coronary vasodilation and inhibition of platelet aggrega-
tion [9,18,38]. A2A activation suppresses activation of immune
cells, including T cells, monocytes, macrophages, PMNs, and
dendritic cells [46]. Investigations in A2A
-/- mice have revealed
its nonredundant role in downregulating acute inflammatory
processes [47]. Activation of A2A mediates protection from I/R
injury in various tissues, including lung [48].
Critical Care    Vol 12 No 5 Schepp and Reutershan
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A2A agonist attenuated increases in both PMN sequestration
into the lung and microvascular permeability. Also clinically
relevant is the fact that treatment after induction of ALI had
similar effects, albeit to a lesser extent [49]. A critical role in
maintaining pulmonary fluid homeostasis has been
established in numerous experimental settings. Alveolar fluid
clearance in mice was increased upon A2A activation [22],
and in a canine model of ALI pretreatment with an A2A agonist
or adenosine reduced capillary filtration induced by phorbol
myristate acetate [42]. In accordance with these findings,
treatment  with an A2 agonist completely abolished lung
edema formation after LPS administration in the rabbit lung
[43]. In a murine model of combined pneumonia and hyperoxia
induced ALI, organ damage was attenuated and survival was
prolonged after treatment with an A2A agonist [50].
In a study that provided evidence of a profound anti-inflam-
matory effect of an A2A antagonist in allergic lung inflamma-
tion [51], the authors included experiments with LPS-induced
lung inflammation. Treatment with the antagonist did not have
an effect on BAL fluid counts of PMNs, macrophages, or
lymphocytes. Furthermore, levels of C-X-C chemokine ligand
(CXCL)1 and CXCL2/3 were not significantly altered, but
there was a trend toward lower levels after treatment. Levels
of elastase in BAL fluid (a marker of PMN activation) were
significantly reduced. Wild-type mice challenged with
nebulized LPS exhibited significant accumulation of PMNs in
all three compartments of the lung (pulmonary microvascula-
ture, interstitium, and alveolar space). Pretreatment with a
specific A2A agonist reduced transepithelial migration of
PMNs into the BAL fluid. This effect was abrogated in A2A
-/-
mice and in chimeric mice that expressed A2A only on non-
hematopoietic cells, suggesting that A2A activation on hemato-
poietic cells mediates protection from pulmonary inflammation.
In addition, the same A2A agonist reduced LPS-induced
microvascular permeability and secretion of interleukin-6, tumor
necrosis factor-α, CXCL1, and CXCL2/3 into the BAL fluid
[52]. This highlights a predominant role for A2A in mediating
lung protection in various models of pulmonary inflammation.
At present, there are no data available supporting a role for
A2A in human ALI. However, the fact that specific A2A
agonists are currently being tested in clinical trials for other
diseases makes this receptor an attractive target for
therapeutic advancement in human ALI/ARDS. As with other
immunomodulatory strategies, possible adverse effects that
are associated with the biologic function of A2A, such as
inhibition of platelet aggregation or vasodilation, require
attention. The development of agents that allow topical
application to the lung via aerosol may be one concept to
overcome these adverse effects.
A2B - sometimes good, sometimes bad?
A2B exhibits a broad expression pattern, including central
nervous system, intestine, and lung. High levels of expression
are found in the vasculature and on macrophages [53]. Its
affinity for adenosine is the lowest of all four ARs [54,55]. In
contrast to the other ARs, A2B activation requires adenosine
concentrations that are not reached under physiological
conditions. A2B is coupled to both Gs and Gq proteins,
activating adenylate cyclase and phospholipase C, respec-
tively. Consistent with an endothelial expression of A2B, its
activation induces vasodilation [9,18,38].
In A2B gene deficient mice, baseline plasma levels of pro-
inflammatory cytokines were greater than in wild-type mice.
Upon LPS stimulation, the inflammatory response in A2B
-/-
mice was substantially enhanced when compared with wild-
type mice, implicating A2B as a negative regulator of relevant
cytokines. In addition, leukocytes from A2B
-/- mice exhibited
increased adherence to the vessel wall, suggesting an
important role for A2B in inhibiting leukocyte trafficking to
inflamed tissue [53].
A2B is critical for the protective effects of adenosine in murine
VILI. Treatment of mechanically ventilated mice with an A2B
antagonist increased pulmonary microvascular permeability
and decreased survival [35]. A2B was upregulated in
response to a ‘lung-destructive’ ventilation strategy in rats,
whereas its expression level remained unchanged with lung-
protective ventilation [34]. Together with elevated adenosine
levels during mechanical ventilation, A2B appears to provide
endogenous protection from VILI that might be overwhelmed
by lung-hostile ventilation.
In contrast to these findings, treatment of ADA-/- mice with
A2B antagonists led to attenuation in pulmonary inflammation
[56]. In addition, the authors were able to demonstrate similar
proinflammatory properties of A2B activation in murine
bleomycin-induced lung injury [56]. These findings underline
the complexity of adenosine signaling. A2B - with its low
affinity - is certainly a key player in the differential response to
varying extracellular adenosine levels, but information on A2B
function in human pulmonary disease is lacking.
A3 - good and bad?
A3 is ubiquitously expressed. The highest levels of human A3
are detected in lung and liver. Signaling requires pertussis-
toxin sensitive Gi protein, leading to a reduction in adenylate
cyclase activity. Activation of A3 also leads to stimulation of
phospholipase C via Gq proteins [9,18,38].
The biologic functions of A3 in inflammatory disease are
ambiguous. In I/R injury there is evidence for both protective
[57,58] and exacerbating effects [59]. Pulmonary inflamma-
tion was attenuated by pharmacological blockade or genetic
removal of A3, suggesting a proinflammatory effect of A3.
Eosinophils and, although less pronounced, all other leuko-
cytes - including PMNs - were reduced in the BAL fluid after
treatment with an A3 antagonist [60].
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that migrate toward an fMLP (N-formyl-Met-Leu-Phe) gradient
exhibit an accumulation of A3 molecules on the leading edge,
the location where they bind adenosine generated through
extracellular hydrolysis of ATP [61]. Because PMN migration
is pivotal in ALI, A3 appears to be an interesting target, but
current knowledge on A3 function in ALI is limited. A recent
study investigated the role of A3 in a murine model of sepsis
[62]. In that study A3
-/- mice exhibited reduced pulmonary
damage, and PMN migration into the lung was decreased.
Leukocytes of these mice also failed to accumulate
adequately in the intra-abdominal compartment, but survival
of A3
-/- mice was prolonged. The authors attributed prolonged
survival to the reduced secondary lung damage that had been
observed in A3
-/- mice [62]. Data on A3 function in human
pulmonary disease are not available. However, degranulation
of human PMNs has been demonstrated to be under the
control of A3 [63,64], which suggests that A3 might well be
involved in pulmonary inflammation.
Clinical implications
Selective agonist and antagonists for all four ARs are
available [39]. In addition, gene-deficient mice provide an
excellent tool for further elucidation of adenosine-mediated
immunomodulation and validation of therapeutic approaches
to ALI. However, major limitations should be considered
before attempting to recapitulate experimental findings in
humans. Numerous animal models have been established to
study the pathophysiology of acute pulmonary inflammation.
These models mimic several aspects of the human disease,
including neutrophil infiltration, microvascular permeability, or
release of chemotactic cytokines. However, clinical
parameters such as pulmonary gas exchange and radiological
alterations are not monitored in most experimental studies. In
addition, significant interspecies differences in AR amino acid
sequences may be of functional significance. For example,
activation of human A2B induces mast cell activation [65],
whereas in mice this effect is mediated by A3 [66].
The expression pattern of AR on different cell types has not
been investigated systematically. PMNs appear to be the
predominant cell type that contributes to AR-dependent
pulmonary inflammation. In addition, pulmonary endothelial
cells are involved [52] and may be an attractive target for
pharmacologic compounds that are administered topically (for
instance, by inhalation). The relevance of other AR-expressing
cells such as mast cells remains to be demonstrated.
Adenosine has profound influences not only on the immune
system but also on hemostasis, hemodynamics, and the
central nervous system. Thus, interference with this signaling
complex may be associated with serious adverse effects. In
ALI topical application of an aerolized agent with low
systemic bioavailability might be a promising strategy.
Some agents that interfere with adenosine signaling are
currently at various stages of clinical trials. Although these
trials are aimed at diseases other than ALI - such as heart
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Figure 2
AR-dependent pathways involved in PMN trafficking and fluid homeostasis during acute pulmonary inflammation. Presented is a three compartment
model (capillary, interstitium, and alveolar space). Red indicates inhibitory effects, and green indicates stimulatory effects. AR, adenosine receptor;
PMN, polymorphonuclear cell.failure, hypertension, renal failure, Parkinson’s disease, pain,
and asthma [67] - they will probably provide a first insight into
the anti-inflammatory capacity and adverse effects of these
agents in the clinical setting.
Conclusions
Adenosine and ARs are involved in various immunoregulatory
processes, including pulmonary inflammation (Figure 2). ARs
exert both proinflammatory and anti-inflammatory effects,
depending on the type of receptor and the experimental
setting. Profound protective effects of adenosine have been
shown in systems representative of VILI and other models of
primary and secondary ALI. A2A and, to a lesser extent, A2B
appear to be major mediators of protective effects during ALI.
The marked interference of adenosine signaling in pulmonary
fluid homeostasis and PMN trafficking supports a key role in
the pathophysiologic cascade of ALI. The availability of
pharmacologic agents that selectively target ARs encourages
further experimental and clinical investigation. Detailed
characterization of adenosine-dependent pathways in ALI will
help to develop innovative strategies for the treatment of
ALI/ARDS.
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